United States · Platforms & data · MarketBeat

ProKidney Targets Q2 2027 Phase III Readout as Rilparencel Enrollment Surpasses 500

Published by MarketBeat · United States 1 h ago

ProKidney (NASDAQ:PROK) said it remains on track to report top-line results from the interim analysis of its Phase III PROACT 1 study in the second quarter of 2027, following…

Read the full article on MarketBeat Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)

Also worth reading

The Motley Fool

ProKidney Targets Q2 2027 Phase III Readout as Rilparencel Enrollment Surpasses 500

Share

Also worth reading

Can nVent Electric Become the Next Vertiv?

The real way to tell if Amazon’s AI spending is paying off

Top Performing Defensive Stocks

Earnings call transcript: Nebras Energy tops revenue estimates in Q3 2026

Gen Korean BBQ’s next chapter comes with wagyu, buffets and new names

Novartis Raises Guidance After Trial Setbacks Hit Profit